
|Articles|April 1, 1998
- Psychiatric Times Vol 15 No 4
- Volume 15
- Issue 4
Learning the Shapes
Learning the Shapes - Poetry of the Times
Advertisement
Five students
wear short white coats,
pockets bulging notecards,
tuning forks, new stethoscopes.
Demanding consent
we snap on latex gloves,
smear index fingers with K-Y,
turn them over, spread them apart
and enter alone, one by one
to learn the shapes inside:
smooth chestnut, soft orange,
stone in a muddy field.
After wiping off the jelly
we wash our hands clean,
examining fingers sensitive
as a blind bluesman
who hears each note
an instant before
touching a tight steel string.
© CME LLC
4/98
Articles in this issue
over 28 years ago
Inside Outover 28 years ago
Executing the Mentally Illover 28 years ago
SAMHSA Study Uncovers Increasing Substance Abuse Among Young Girlsover 28 years ago
Turf War: Will State Hospital Patients Suffer?over 28 years ago
Is There a Common Basis for All Addictions?over 28 years ago
New Prescription for Paraphilia?over 28 years ago
PTSD in Survivors of Rwanda's 1994 WarAdvertisement
Related to this article

Bessel van der Kolk, MD, argues that trauma is rooted in attachment and that psychedelic-assisted therapy may help where medications have not.

Emestedastat did not significantly slow disease progression, but a prespecified analysis showed a higher rate of zero CDR-SB progression.

In this CME article, explore the clinical evidence and ethical reasoning to guide use of long-acting injectable antipsychotics in patient care.

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Why Depression Subtypes Matter: Lessons From 25 Years in the Clinic
2
Treatment of Repetitive Behaviors in Autism: Where Does the Evidence Stand?
3
DT-120 in Anxiety and Depression: Phase 3 Efficacy and Safety Findings
4
Podcast: Bessel van der Kolk, MD, on Trauma, Attachment, and the Limits of Pharmacotherapy for PTSD
5



